Found: 14
Select item for more details and to access through your institution.
Control ofAtm-/-thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 203, doi. 10.1007/s00280-004-0870-6
- By:
- Publication type:
- Article
Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 213, doi. 10.1007/s00280-004-0844-8
- By:
- Publication type:
- Article
Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 222, doi. 10.1007/s00280-004-0861-7
- By:
- Publication type:
- Article
Magnesium and potassium homeostasis during cisplatin treatment.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 231, doi. 10.1007/s00280-004-0899-6
- By:
- Publication type:
- Article
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 237, doi. 10.1007/s00280-004-0836-8
- By:
- Publication type:
- Article
Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible?
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 244, doi. 10.1007/s00280-004-0858-2
- By:
- Publication type:
- Article
Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-a and translocating PKC-d.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 251, doi. 10.1007/s00280-004-0863-5
- By:
- Publication type:
- Article
Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-alpha and translocating PKC-delta.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 271, doi. 10.1007/s00280-004-0875-1
- By:
- Publication type:
- Article
Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 277, doi. 10.1007/s00280-004-0878-y
- By:
- Publication type:
- Article
DNA damage, c-mycsuppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 286, doi. 10.1007/s00280-004-0877-z
- By:
- Publication type:
- Article
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 295, doi. 10.1007/s00280-004-0871-5
- By:
- Publication type:
- Article
Oxaliplatin activity in head and neck cancer cell lines.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 3, p. 301, doi. 10.1007/s00280-004-0847-5
- By:
- Publication type:
- Article